NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY – Get Free Report)’s share price hit a new 52-week high during trading on Tuesday . The company traded as high as $7.30 and last traded at $6.75, with a volume of 937413 shares traded. The stock had previously closed at $5.87.
NovaBay Pharmaceuticals Stock Performance
The stock has a market cap of $1.34 billion, a P/E ratio of -1.07 and a beta of 0.09. The business has a 50 day simple moving average of $2.70 and a 200-day simple moving average of $1.74.
Institutional Trading of NovaBay Pharmaceuticals
Several hedge funds have recently made changes to their positions in the company. Ground Swell Capital LLC bought a new position in shares of NovaBay Pharmaceuticals during the 3rd quarter worth $25,000. Apollon Wealth Management LLC purchased a new stake in NovaBay Pharmaceuticals during the third quarter valued at about $35,000. Finally, C2C Wealth Management LLC lifted its holdings in NovaBay Pharmaceuticals by 78.2% during the second quarter. C2C Wealth Management LLC now owns 98,000 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 43,000 shares during the last quarter. 23.25% of the stock is currently owned by institutional investors.
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, non-antibiotic anti-infective products designed to regulate the innate immune response. Leveraging its proprietary Aganocide® Technology, the company’s synthetic antimicrobial compounds target and neutralize pathogens without contributing to antibiotic resistance. NovaBay’s research and development efforts concentrate on ophthalmic, dermatological and wound care applications, aiming to address unmet needs in infection control and inflammation management.
The company’s primary commercial products include Avenova®, an eyelid and lash cleaning solution indicated for managing chronic blepharitis and meibomian gland dysfunction, and NeutroPhase®, a pure hypochlorous acid wound and skin cleanser used in acute and chronic wound irrigation.
See Also
- Five stocks we like better than NovaBay Pharmaceuticals
- You Still Think Silver’s a Joke? Watch What Happens Next.
- A U.S. “birthright” claim worth trillions – activated quietly
- A month before the crash
- Do not delete, read immediately
- YDES Could Be 2026’s Biotech Breakthrough
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
